A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
Public ClinicalTrials.gov record NCT06780306. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Controlled, Multicenter, Dose Optimization Study of TTAX03 in the Treatment of Mild to Moderate Dry Eye Disease (DED)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness. Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness. Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.
Study identification
- NCT ID
- NCT06780306
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2024
- Primary completion
- Jan 29, 2026
- Completion
- Jan 29, 2026
- Last update posted
- Feb 10, 2026
2024 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University California Berkeley | Berkeley | California | 94720 | — |
| Advanced Research, LLC. | Deerfield Beach | Florida | 33064 | — |
| Southwest Eye Care | Chaska | Minnesota | 55318 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Eye Associates of North Jersey | Dover | New Jersey | 07801 | — |
| Northern New Jersey Eye Institute | South Orange | New Jersey | 07079 | — |
| Wilmington Eye at Brunswick Forest | Leland | North Carolina | 28451 | — |
| CORE, Inc. / Vita Eye Clinic | Shelby | North Carolina | 28150 | — |
| Westlake Eye Specialists | Austin | Texas | 78749 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06780306, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06780306 live on ClinicalTrials.gov.